研究者詳細 - 赤塚　美樹

講演・口頭発表等 - 赤塚　美樹

分割表示 109 件中 81 - 100 件目／全件表示 >>

骨髄移植症例に誘導されるGVL効果の解析．招待有り国際会議

赤塚　美樹

第67回日本癌学会総会シンポジウム

Minor Antigen 反応性CTLの移植医療への関与招待有り国際会議

赤塚　美樹

第31回日本造血細胞移植学会総会、シンポジウム

Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy. 国際共著国際会議

Lung-Ji Chang, Chun-Rong Tong, Jih-Luh Tang, Yoshiki Akatsuka, Shuhong Han, Yin Liang, Chi-Cheng Li, Lujia Dong, Tong Wu, Dao-Pei Lu

Blood 2007年11月16日 American Society of Hematology

開催年月日： 2007年11月

記述言語：英語

<title>Abstract</title>
Differential graft versus host response after bone marrow transplantation (BMT) is key to leukemia patient survival. The development of specific graft versus leukemia response targeting tissue-specific minor histocompatibility antigens (mHAgs) is a novel therapeutic approach to treating hematopoietic malignancies. A pilot intensive immune cell therapy was applied to an acute myeloid leukemia (AML) patient who relapsed around day 43 after receiving unrelated allogeneic BMT with three allele disparities for HLA-A, C and DQB1. The patient received more than thirty infusions of dendritic cell-co-cultured donor-derived immune cells including cytotoxic T lymphocytes (CTL) generated against AML lysate-pulsed dendritic cells (DC), AML-DC fusion, and DC pulsed with HLA-A*2402-restricted ACC1Y mHAg epitope. The latter was expressed by recipient but not by donor hematopoietic cells. ACC1Y-peptide-major histocompatibility complex (MHC) multimer staining detected CTL in the patients peripheral blood at different time points during treatment. Four months after the first mHAg-CTL infusion, CTL-resistant AML cells were detected in relapsed pleural effusion and peripheral blood. Further analysis of the relapsed AML cells revealed complete loss of surface class I HLA-A*2402 and class II HLA molecules. Although the AML-specific immune cells were effective in killing the original AML in CTL assays in vitro, the late relapsed AML became resistant to the early AML-primed CTL. This result suggests that rapidly evolving AML cells may escape the intensive anti-leukemia allo-immune pressure including the mHAg-specific CTL through selective loss of A*2402 expression - the ACC1Y-restricted HLA locus. As the patient suffered ongoing multi-focal extramedullary relapse in muscles, sub-mucosal tissue, intestine, spinal cord, and brain, rare cancer cells resistant to mHAg-specific CTL could evolve quickly. Our study indicates that immune escape through diminished HLA expression, which resulted in lack of cancer cell killing by AML-specific immune cells, including the mHAg-restricted CTL, had developed during the therapy. Therefore, leukemia patients with high load of AML or multi-focal extramedullary relapse may not endure prolonged benefit from a single arm immune cell therapy.

GVHDを増強せずにGVL効果を高める治療法の可能性招待有り国際会議

赤塚　美樹

第69回日本血液学会・第49回日本臨床血液学会シンポジウム

造血器腫瘍に対する細胞免疫療法の今後招待有り国際会議

赤塚　美樹

第69回日本血液学会・第49回日本臨床血液学会

臍帯血移植後に増加するCD16+CD56‐NK細胞がGvL効果に関与している

盧緒章, 近藤恭夫, 高松博幸, 大畑欣也, 石山謙, 山崎宏人, 高見昭良, 奥村廣和, 赤塚美樹, 中尾眞二

臨床血液 2007年9月30日

BCL2A1にコードされる血液細胞特異的マイナー組織適合抗原のメラノーマにおける異所性発現(Aberrant Expression of BCL2A1-Encoded Minor Histocompatibility Antigens in Melanoma Cells)

鳥飼宏基, 赤塚美樹, 谷田部恭, 亀井美智, 森島泰雄, 小寺良尚, 高橋利忠, 葛島清隆

日本癌学会総会記事 2007年8月日本癌学会

マイナー組織適合抗原を標的とした免疫療法．招待有り国際会議

赤塚　美樹

第55回日本輸血・細胞治療学会総会

上咽頭癌の腫瘍局所に浸潤したEBV溶解感染抗原に特異的なCD8陽性T細胞の解析

伊藤嘉規, 不破信和, 岡村文子, 町, 谷田部恭, 赤塚美樹, 辻村邦夫, 高橋利忠, 葛島清隆

日本癌学会総会記事 2006年9月日本癌学会

Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT. 国際共著国際会議

Seitaro Terakura, Makoto Murata, Tetsuya Nishida, Nobuhiko Emi, Yoshiki Akatsuka, Stanley R. Riddell, Yasuo Morishima, Yoshihisa Kodera, Tomoki Naoe

Blood 2004年11月16日 American Society of Hematology

開催年月日： 2004年11月

記述言語：英語会議種別：口頭発表（招待・特別）

<title>Abstract</title>
We recently identified a human minor histocompatibility (H) antigen encoded by the UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17) gene. UGT2B17 is a metabolic enzyme that is highly expressed in liver and colon, and at low levels in hematopoietic cells. UGT2B17 conjugates exogenous and endogenous compounds including steroid hormones and facilitates their elimination. The immunogenicity of the UGT2B17 was due to differential expression of the protein in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene in the recipient. Deletion of this gene in a subset of normal individuals suggested two mechanisms by which UGT2B17 could affect the outcome of allogeneic BMT. First, the expression of UGT2B17 in recipient but not donor cells could provide minor H antigens and increase GVHD. Second, the presence of UGT2B17 in the donor or recipient could affect the metabolism, function, or toxicity related to endogenous hormones or drugs administered with BMT. The purposes of this study were to determine the frequency of homozygous UGT2B17 deletion in healthy individuals and patients with hematological disease and whether a deficiency of UGT2B17 in donor and/or recipient affected the outcome of allogeneic BMT. A total of 435 recipients were selected from the patients who received unrelated BMT through the Japanese Marrow Donor Program between January 1993 and March 2000. Selection criteria were (1) matched at HLA-A, B, C and DRB1 genotypes, (2) unmanipulated marrow graft, (3) cyclosporine A or tacrolimus as GVHD prophylaxis, and (4) available DNA was stored. DNA from a total of 358 of the donors was also available. Homozygous deletion of the UGT2B17 gene determined by SSP-PCR was found in 320 (84.8%) of 377 donors and 358 (82.3%) of 435 patients (P=0.32, χ2 test). These frequencies of UGT2B17 deletion were substantially higher than the 11% observed in the Caucasian population in a previous study. A multivariate analysis (Cox proportional hazard model) showed no significant association between UGT2B17-mismatch in the GVHD direction and the incidence of acute GVHD (grade II-IV or III-IV), chronic GVHD, relapse, or survival. However, a deletion of UGT2B17 in the donor was a favorable factor for transplant-related mortality (TRM) (relative risk, 0.530; 95% CI, 0.334 to 0.841; P=0.007), survival (0.567; 0.387 to 0.831; P=0.036) and disease-free survival (DFS) (0.647; 0.443 to 0.945; P=0.024). We also analyzed these outcomes in the subset of patients with standard-risk malignant disease by the Kaplan-Meier method. TRM, survival, and DFS at eight years after transplantation were 23.7% for patients transplanted from a UGT2B17-deleted donor vs 52.9% for patients with a UGT2B17-positive donor (P=0.001); 68.3% vs 37.5% (P=0.0009); and 66.9% vs 37.5% (P=0.0009), respectively. These data suggest that the UGT2B17 enzyme in donor-derived blood cells may affect the metabolism of exogenously administered or endogenous molecules and adversely influence the outcome of unrelated BMT. Analysis in another patient population will be important to confirm our results.

サイトメガロウイルス(CMV)-pp65蛋白由来の新規CTLエピトープの同定

近藤英生, 赤塚美樹, 葛島清隆, 辻村邦夫, 田嶋公平, 谷本光音, 高橋利忠

日本免疫学会総会・学術集会記録 2003年11月 (NPO)日本免疫学会

サイトメガロウイルス(CMV)-pp65蛋白由来のCTLエピトープの同定

近藤英生, 赤塚美樹, 葛島清隆, 辻村邦夫, 田嶋公平, 谷本光音, 森島泰雄, 高橋利忠

基盤的癌免疫研究会総会抄録 2003年7月日本がん免疫学会

マイナー組織適合抗原特異的CTLクローンの樹立と,リンケージ解析を用いた抗原遺伝子座の同定

赤塚美樹, 近藤英生, 田地浩史, 辻村邦夫, 森島泰雄, 小寺良尚, 葛島清隆, 高橋利忠

日本癌学会総会記事 2002年10月日本癌学会

TL拘束性TCRαβ型CTLの抗原認識機構の解析

辻村邦夫, 小幡裕一, 西田敬子, 松平康枝, 近藤英生, 赤塚美樹, 葛島清隆, 高橋利忠

日本免疫学会総会・学術集会記録 2002年10月 (NPO)日本免疫学会

The status of the tumor microenvironment changes dynamics of the balance of CD8(+) T cells and Treg cells in renal cell carcinoma 国際会議

Sugiyama Daisuke, Muramatsu Tomoaki, Kobayashi Yoichi, Sassa Naoto, Maruyama Shoichi, Goto Momokazu, Akatsuka Yoshiki, Nishikawa Hiroyoshi

CANCER RESEARCH 2020年8月

Tumor-infiltrating lymphocytes in renal cancer patients demonstrate a diverse PD-1 expression and characteristic Treg classification 国際会議

Sugiyama Daisuke, Muramatsu Tomoaki, Kobayashi Yoichi, Sassa Naoto, Maruyama Shoichi, Goto Momokazu, Akatsuka Yoshiki, Nishikawa Hiroyoshi

CANCER RESEARCH 2019年7月

不適合 HLA-DP 抗原を標的とする同種移植後細胞免疫療法の検討

勝山直哉, 楫屋良子, 白石圭子, 西尾信博, 一戸辰夫, 赤塚美樹

第42回日本造血細胞移植学会総会 2020年3月6日

多発性骨髄腫の免疫微小環境を考慮した治療戦略

赤塚美樹

第84回日本血液学会学術集会イブニングセミナー1-3 2022年10月14日

遺伝子改変T細胞療法の現状と将来招待有り

赤塚美樹

Okayama-Hiroshima Immunotherapy Symposium 2020年2月1日

遺伝子改変T細胞療法の現状とこれから招待有り

赤塚美樹

岐阜県造血障害・免疫療法セミナー 2019年10月3日

　前のページ - 次のページ　

<赤塚 美樹>

講演・口頭発表等 - 赤塚 美樹

<赤塚　美樹>

講演・口頭発表等 - 赤塚　美樹